Physician profile
David E Fisher
NPI 1396717765
$2,760.31
in general payments reported to CMS, 2019-2025
33 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $339 · 2021: $619 · 2022: $540 · 2023: $238 · 2024: $359 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $584.26 | 2019-2025 | |
| Glaxosmithkline, LLC. | $438.79 | 2020-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $279.24 | 2021-2025 | |
| Novo Nordisk INC | $196.21 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $149.04 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $135.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $133.24 | 2020-2024 | Airsupra |
| Medtronic, INC. | $102.18 | 2023-2024 | Intellis Adaptivestim |
| Amgen INC. | $79.19 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $65.71 | 2022-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $64.60 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $49.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $48.65 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $48.05 | 2022-2024 | Steglatro, Belsomra, Gardasil 9 |
| Alphatec Spine, INC | $37.09 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $31.88 | 2021 | |
| Horizon Therapeutics Plc | $29.08 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.19 | 2022 | |
| Si-Bone, INC. | $23.39 | 2021 | |
| Lilly USA, LLC | $23.10 | 2021 | |
| Kaleo, INC. | $21.39 | 2022 | |
| Vyera Pharmaceuticals, LLC | $21.09 | 2019 | |
| Pharmacosmos Therapeutics INC. | $20.62 | 2022 | |
| Kyowa Kirin, INC. | $20.29 | 2020 | |
| Edwards Lifesciences Corporation | $19.94 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.74 | 2020 | |
| Amarin Pharma, INC. | $17.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.37 | 2023 | Trintellix |
| Antares Pharma, INC. | $14.44 | 2020 | |
| Genentech USA, INC. | $14.25 | 2020 | |
| Esperion Therapeutics, INC. | $13.85 | 2021 | |
| Allergan, INC. | $10.99 | 2020 | |
| Neuronetics, INC. | $6.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.